Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:

Interneuron Redux Settlement Offer Denied Due To Valuation "Uncertainty"

  • News

Executive Summary

The unpredictability of Interneuron's future cash-flow served as a basis of Eastern District of Pennsylvania Judge Louis Bechtle's Sept. 27 decision to deny the company's proposed settlement for diet drug Redux medical claims.

You may also be interested in...



AHP Redux Litigation Roster Adds Fraud Suit From Interneuron

American Home Products' lingering Redux liability now includes a fraud lawsuit brought by its former marketing partner Interneuron.

AHP Redux Litigation Roster Adds Fraud Suit From Interneuron

American Home Products' lingering Redux liability now includes a fraud lawsuit brought by its former marketing partner Interneuron.

AHP Redux Settlement Doubles Cash Payments For Use Of Drug Over 60 Days

Patients who used American Home Products' Redux or Pondimin for more than 60 days would be eligible to receive a cash payment of $6,000 if an echocardiogram shows heart valve regurgitation, while those who used the drugs for 60 days or less could receive $3,000, under a settlement proposed by AHP.
Table

View full table

Related Content

Pink Sheet
Tags:
UsernamePublicRestriction

Register

PS034921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By